New HIV vaccine strategy aims to trigger powerful antibodies
NCT ID NCT05471076
First seen Jun 25, 2026 · Last updated Jul 09, 2026 · Updated 3 times
Summary
This early-phase trial is testing two experimental HIV vaccines in 52 healthy adults without HIV. The goal is to see if the vaccines are safe and can stimulate the immune system to produce broadly neutralizing antibodies, which are key to fighting many HIV strains. Participants receive different doses of the vaccines or a placebo, and researchers will monitor side effects and immune responses over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Experimental HIV vaccines (426c.Mod.Core-C4b and BG505 SOSIP.GT1.1 gp140) with an adjuvant (3M-052-AF + alum)
- What this could lead to
- If successful, this could point toward a vaccine that trains the immune system to make broadly neutralizing antibodies against many HIV strains.
- What could go wrong
- This is a very early phase 1 trial with only 52 participants, focused on safety and immune response, not on preventing HIV. Many vaccine candidates fail at this stage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Alabama CRS
Birmingham, Alabama, 35222, United States
-
Bridge HIV CRS
San Francisco, California, 94102, United States
-
Brigham and Women's Hospital Vaccine CRS (BWH VCRS)
Boston, Massachusetts, 02115-6110, United States
-
Columbia P&S CRS
New York, New York, 10032, United States
-
Seattle Vaccine and Prevention CRS
Seattle, Washington, 98104, United States
-
The Ponce de Leon Center CRS
Atlanta, Georgia, 30308-2012, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a single HIV pill tame the epidemic in africa?
- Could a shorter drug course beat a longer one for a deadly fungal infection?
- A kinder, more personal touch may help people with HIV stay in care — a large trial in zambia puts it to the test
- Can tracking HIV's genetic fingerprints reveal where the epidemic is heading?
- Can a new drug, GS-0415, help keep HIV in check? a First-in-Human trial aims to find out
- Could a shot replace daily HIV pills? new trial tests injectable combo